Jazz Pharmaceuticals (BSP:J2AZ34) Inventories, Raw Materials & Components: R$182 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:J2AZ34 Jazz Pharmaceuticals PLC BSP:J2AZ34
44 GF Score
Price R$87.12
GF Value R$51.81
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Inventories, Raw Materials & Components?

Jazz Pharmaceuticals BSP:J2AZ34 -2.71% 44 Inventories, Raw Materials & Components is R$182 Mil as of Jun. 2026. GuruFocus rates BSP:J2AZ34 with a GF Score™ of 44/100 and a GF Value™ of R$51.81 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Jazz Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Jun. 2026 was R$182 Mil.

Jazz Pharmaceuticals's quarterly raw materials increased from Dec. 2025 (R$120 Mil) to Mar. 2026 (R$144 Mil) and increased from Mar. 2026 (R$144 Mil) to Jun. 2026 (R$182 Mil).

Jazz Pharmaceuticals's annual raw materials declined from Dec. 2023 (R$125 Mil) to Dec. 2024 (R$123 Mil) and declined from Dec. 2024 (R$123 Mil) to Dec. 2025 (R$120 Mil).

Jazz Pharmaceuticals Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Inventories, Raw Materials & Components Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.86 109.03 125.41 123.00 119.82

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.43 118.34 119.82 144.34 181.91
BSP:J2AZ34
44GF Score
Jazz Pharmaceuticals PLC BSP:J2AZ34
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of R$182 Mil mean?
Jazz Pharmaceuticals (BSP:J2AZ34) has a Inventories, Raw Materials & Components of R$182 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Inventories, Raw Materials & Components too high?
Jazz Pharmaceuticals' current Inventories, Raw Materials & Components is R$182 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Inventories, Raw Materials & Components compare to BBIO and ASND?
Jazz Pharmaceuticals' Inventories, Raw Materials & Components of R$182 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Inventories, Raw Materials & Components is R$182 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (BSP:J2AZ34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$51.81, compared to a current price of R$87.12 — trading 68.2% above its estimated fair value. The current Inventories, Raw Materials & Components is R$182 Mil. Jazz Pharmaceuticals' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Jazz Pharmaceuticals (BSP:J2AZ34), the current Inventories, Raw Materials & Components is R$182 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (BSP:J2AZ34) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of R$87.12 is trading 68.2% above its estimated GF Value™ of R$51.81. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BSP:J2AZ34:

  • Inventories, Raw Materials & Components: R$182 Mil
  • GF Value™: R$51.81 vs. price of R$87.12 (68.2% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the BSP:J2AZ34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
44GF Score

Get the complete analysis for BSP:J2AZ34

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$87.12
Price
R$51.81
GF Value